Liver resection for intermediate hepatocellular carcinoma

Table 2 Studies comparing liver resection for Barcelona Clinic Liver Cancer A and B

Ref.	Group	Median OS (mo)	Median DFS (mo)	Accumulative DFS	Intrahepatic recurrence	Extra-hepatic recurrence	Survival rate	Mortality	Morbidity
Ng et al[38]	BCLC A: 404	A: 83.5 (67.9-99.1)	A: 77 (66, 87.9)	A: 80%, 64%, 40%	A: 139/404 (34.4%)	A: 95/404 (23.5%)	1-, 3- and 5- yr	A: 11/404 (2.7%)	93/404 (23.0%)
	BCLC B: 380	B: 36.9 (28.9-44.8)	B: 15.6 (10.8-20.4)	B: 54%, 38%, 26%	B: 199/380 (52.4%)	B: 110/380 (29.0%)	A: 88%, 76%, 58%	B: 9/380 (2.4%)	104/380 (27.4%)
		Sig	Sig	Sig	Sig	No sig	B: 74%, 50%, 39%	No sig	No sig
							Sig
Cho et al[39]	BCLC A: 169	NR	NR	1-, 3- and 5- yr	NR	NR	1-, 3- and 5- yr	A: 1/169 (0.6%)	NR
	BCLC B: 61			A: 71.4%, 51.8%, 44.1%			A: 87.5%, 69.5%, 59.0%	B: 1/61 (1.6%)
				B: 58.3%, 40.0%, 31.7%			B: 85.0%, 59.3%, 52.9%	No sig
				No sig			No sig
Torzilli et al[44]	BCLC A: 61	NR	NR	A: 77%, 30%	A: 19/61 (31.14%)	A: 2/61 (3.3%)	1- and 3-yr	A: 0	A: 13/61 (21.3%)
	BCLC B: 24			B: 75%, 35%	B: 6/24 (25%)	B: 3/24 (12.5%)	A: 91.6%, 81%	B: 0	B: 7/24 (29.2%)
				No sig	No sig	No sig	B: 85%, 67%	No sig	No sig
							No sig
Wang et al[24]	BCLC A: 202	A: Can’t estimate	A: NR	A: NR	A: NR	A: NR	A: Cannot be estimated	NR	NR
	BCLC B: 243	B: 60.4	B: NR	B: NR	B: NR	B: NR	B: 1-, 3- and 5- yr
							(81.5%, 64.4%, 50.5%)
Wei et al[40]	BCLC A: 52	NR	NR	1-, 2- and 3-yr	NR	NR	1-, 2- and 3-yr	NR	NR
	BCLC: 51			A: 77.8%, 61.4%, 48.9%			A: 86.5%, 75.0%, 69.2%
				B: 70.2%, 55.8%, 45.4%;			B: 84.3%, 68.6%, 54.9%
				No sig			No sig
Chang et al[43]	BCLC A: NR	NR	NR	5 yr	The 1-, 2-, 3- and 5-yr recurrence rates were 44.2%, 54.5%, 60.6%, and 68.1%, respectively, in BCLC stage B patients		1-, 2-, 3- and 5-yr	NR	NR
	BCLC B: 318			B: 28.6%			B: 81.2%, 68.1%, 59.4%, 46.5%
Ma et al[49]	BCLC A: 92	A: Cannot be estimated	A: Cannot be estimated	NR	NR	NR	NR	NR	NR
	BCLC B: 178	B: 27.9 ± 3.1 (21.8-33.9)	B: 16.8 ± 1.65 (13.6-20.0)
Torzilli et al[41]	BCLC A: 777	NR	NR	1-, 3- and 5-yr	NR	NR	1-, 3- and 5-yr	30 d	Not significant in major complications
	BCLC B: 633			A: 77%, 41%, 21%			A: 9 5%, 80%, 61%	A: 1.6% vs B: 3.1%
				B: 63%, 38%, 27%			B: 88%, 71%, 57%	No sig
				Sig			Sig
Cucchetti et al[35]	BCLC A: NR	B: 35 (26-42)	NR	NR	NR	NR	1-, 3- and 5-yr	NR	NR
	BCLC B: 247						B: 77.8%, 48.7% 33.8%
Yamashita [42]	BCLC A: Cannot be estimated	NR	NR	5-yr	Recurrence rate		5 yr	B: 2/53 (3.8%)	B: 13/53 (24.5%)
	BCLC B: 53			B: 24%	B: 32/53 (62%)		B: 35%

OS: Overall survival; DFS: Disease-free survival; A: Patients with HCC of BCLC A; B: Patients with HCC of BCLC B; NR: Not reported; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; Sig: Significant difference.